Retinal Degeneration Fund helps in accelerating life-changing outcomes for people with retinal degenerations through direct mission-related investments in therapeutic companies. The Retinal Degeneration Fund (RD Fund) is a not-for-profit subsidiary of the Foundation Fighting Blindness launched in 2018.
Perceive Pharma operates as a pharmaceutical company. Perceive Pharma develops innovative small molecule neuroprotective treatments.
NVasc
Venture Round in 2023
NVasc is an early-stage ophthalmology company with a focus on treating blindness. It specializes in treating the leading causes of blindness through choroidal and retinal revascularization. The company has acquired the research rights to growth factors (NVB001 and NVB002) that have been shown to encourage the growth of non-leaking new vessels in the retina and choroid in mouse models of ischemic eye diseases. The company is planning to manufacture NVB001 which can be used in toxicokinetic studies and in early clinical trials in humans.
Amber Bio
Seed Round in 2023
Amber Bio is a biotechnology company pioneering new gene editing modalities using multi-kilobase edits to reach previously undruggable patient populations.
Perceive Biotherapeutics
Series B in 2023
Perceive Biotherapeutics is a biotechnology company focused on developing innovative ophthalmic therapeutics aimed at treating various eye diseases. The company leverages novel protective biologies to create a diverse pipeline of therapeutic assets that target significant causes of irreversible blindness. By utilizing multiple therapeutic modalities, Perceive Biotherapeutics seeks to provide medical professionals with effective solutions for improving eye health and preventing vision loss.
SparingVision
Series B in 2022
SparingVision SAS is a biotechnology company based in Paris, France, dedicated to discovering and developing gene therapy-based treatments for inherited retinal diseases that can lead to blindness. Founded in 2016, the company is focused on creating innovative therapies for conditions such as retinitis pigmentosa, the most prevalent form of inherited retinal degeneration, which currently lacks comprehensive treatment options. SparingVision is advancing its lead candidate, SPVN06, which aims to address the needs of the nearly 2 million individuals affected by this rare genetic disorder globally. By targeting the underlying causes of these diseases, SparingVision seeks to improve the quality of life for patients suffering from genetic retinal disorders.
Nacuity Pharmaceuticals
Series B in 2022
Nacuity Pharmaceuticals is a pharmaceutical company that aims to develop a breakthrough treatment for retinitis pigmentosa (“RP”) and potentially other ophthalmological indications. Nacuity has assembled an accomplished team and has received significant financial and technical support from the Foundation Fighting Blindness (FFB). FFB aims to drive research providing prevention, treatments and cures for people affected by blinding retinal diseases. FFB has invested nearly $700 million in this effort Over the last 46 years. FFB is a significant supporter of Dr. Campochiaro’s research and has committed to fund a substantial portion of Nacuity’s Phase 1 and Phase 2 trials through a milestone-based matching program grant to Nacuity in support of our NPI-001 development program.
SalioGen Therapeutics
Series B in 2022
SalioGen Therapeutics is a biotechnology company focused on developing gene therapies for inherited disorders. Utilizing its proprietary Exact DNA Integration Technology (EDIT), the company employs mammal-derived enzymes, known as Saliogase, to facilitate genome engineering. This innovative approach enables the delivery of any size gene through non-viral methods, offering significant advantages in manufacturing and application. SalioGen's technology aims to provide durable, safe, and affordable treatments, potentially transforming the landscape of care for patients with genetic conditions and enhancing the efficiency of cell therapy and biologics manufacturing in the healthcare sector.
Opus Genetics
Seed Round in 2021
Opus Genetics is a gene therapy company focused on addressing challenges related to the manufacturing of treatments for ultra-rare retinal degenerative diseases. By utilizing adeno-associated virus-based gene therapies, Opus aims to provide effective solutions for individuals suffering from blinding conditions. The company's patient-first approach emphasizes the importance of accessibility to these specialized treatments, ensuring that advancements in gene therapy reach those in need efficiently.
Vedere Bio ll
Series A in 2021
Vedere is developing cutting-edge gene therapy products to restore functional vision to patients who have suffered vision loss from Inherited Retinal Degenerations (IRDs), as well as other causes of both genetic and non-genetic vision loss. While the vast majority of ocular gene therapies only limit the rate of inevitable vision loss, we aim to restore lost vision regardless of a patient’s underlying genetics or their stage of disease.
Atsena Therapeutics
Series A in 2020
Atsena Therapeutics is a clinical-stage gene therapy company focused on developing treatments for inherited retinal diseases that can lead to blindness. Their clinical pipeline includes therapies for conditions such as X-linked retinoschisis and GUCY2D-associated Leber congenital amaurosis. Atsena employs an adeno-associated virus (AAV) technology platform, including a novel spreading capsid, to specifically target these retinal disorders. The company aims to prevent vision loss caused by genetic mutations through innovative ocular gene therapy solutions. With a commitment to advancing treatments for some of the most challenging forms of inherited retinal disease, Atsena Therapeutics seeks to improve the lives of patients affected by these conditions.
Stargazer Pharmaceuticals
Series A in 2020
Stargazer Pharmaceuticals is a pharmaceutical company that offers the therapy of standards disorder and manufacturer of pharmaceuticals products. It's also a Manufacturer of pharmaceuticals. The company is currently operating in Stealth mode.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.